Skip to main content
Intercure Ltd. logo

Intercure Ltd. — Investor Relations & Filings

Ticker · INCR ISIN · IL0011063760 LEI · 549300KI5ESXF8F5GP06 TA Manufacturing
Open in API
Filings indexed 334 across all filing types
Latest filing 2021-04-04 Regulatory Filings
Country IL Israel
Listing TA INCR

About Intercure Ltd.

https://www.intercure.co

Intercure Ltd. is a company focused on the production and distribution of pharmaceutical-grade medical cannabis and cannabis-based products. Operating primarily through its wholly-owned subsidiary, Canndoc Ltd., the company is a licensed producer of Good Manufacturing Practice (GMP) certified medical cannabis. Intercure's strategy involves international expansion through strategic partnerships, such as producing and distributing established brands like Cookies in European markets, and through acquisitions to access premium technologies and brands. The company leverages its EU-GMP certified manufacturing facilities to supply its products for medical use across its operational territories.

Recent filings

Filing Released Lang Actions
no trading in the company's shares on Wednesday, April 7, 2021, which is the record date or the capital consolidation
Regulatory Filings
2021-04-04 Hebrew (modern)
The company intends to publish an immediate report regarding a material event
Regulatory Filings
2021-01-26 Hebrew (modern)
INVESTORS PRESENTATION, Q3 2020
Investor Presentation Classification · 1% confidence The document is a detailed presentation containing financial highlights ("Record revenue of 22.5 million NIS," "Operating profit of 6.1 million NIS," "Positive EBITDA of 7.0 million NIS"), operational statistics, market analysis, and clinical trial pipelines. It explicitly summarizes results for "Q3 2020 MEDICAL CANNABIS SEGMENT" and includes charts on gross profit margins over several quarters (Q2-19 through Q3-20). This structure strongly indicates a periodic financial report presentation, likely accompanying an earnings release or an interim report. Since it provides comprehensive segment results and financial metrics for a specific period (Q3 2020), it aligns best with an Interim/Quarterly Report (IR) or the presentation accompanying an Earnings Release (ER). Given the depth of financial data and operational review, it functions as a comprehensive quarterly update, making 'IR' (Interim / Quarterly Report) the most appropriate classification over just 'ER' (Earnings Release, which is usually just the highlights). It is clearly not a 10-K (Annual Report) due to the quarterly focus.
2020-12-03 English
INVESTORS PRESENTATION, Q3 2020
Regulatory Filings Classification · 1% confidence The document text is heavily obfuscated with non-Latin characters, but key structural elements suggest it is a regulatory filing announcement. The presence of company name 'INTERCURE LTD', dates (03/12/2020, 2020-01-13), and references to regulatory bodies/exchanges (www.isa.gov.il, www.tase.co.il) point towards an official disclosure. Crucially, the document length is very short (2459 chars) and it contains phrases that translate roughly to indicating a report is attached or published (e.g., '����� ���� *Intercure_Q3_2020_isa.pdf*'). This strongly aligns with the 'MENU VS MEAL' rule, indicating this is an announcement about a report rather than the report itself. Given the context of regulatory filings (ISA/TASE) and the announcement nature, the most appropriate classification is Report Publication Announcement (RPA), as it announces the release of a document, or RNS if RPA is too specific and it's a general regulatory notice. Since it explicitly announces the publication of a document, RPA is the best fit among the specific options, although RNS is a strong fallback.
2020-12-03 Russian

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.